Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magrolimab + Azacitidine in Higher Risk MDS
NCT04313881Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Sep 2020
- Primary completion
- Sep 2023
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing Magrolimab + Azacitidine with Placebo + Azacitidine (2 arms). Primary endpoints: Complete Remission at 31.01 months and Overall Survival at 32.62 months. Started Sep 2020; status: terminated.
02
Drugs
magrolimab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04313881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04313881.